Core Viewpoint - The Guangxi Zhuang Autonomous Region's Finance Department has significantly increased financial support for the Fangchenggang International Medical Open Experimental Zone, raising a total of 41.22 billion RMB since 2019 to enhance infrastructure and promote high-quality industrial development in the region [1][2] Group 1: Financial Support and Infrastructure Development - The Finance Department has allocated a total of 25.37 billion RMB to support various projects, including the construction of infrastructure for the non-human primate conservation base [1] - The financial support has effectively promoted the construction of infrastructure and improved the comprehensive carrying capacity of the experimental zone, facilitating the accelerated gathering of three main industries: breeding of experimental animals, preclinical drug research, and traditional medicine development [1] - As of April 2025, the experimental zone has registered 264 enterprises, including 23 high-tech enterprises and 50 recognized technology-based small and medium-sized enterprises [1] Group 2: Healthcare and Medical Services - The Finance Department has also allocated 13.55 billion RMB to support major healthcare projects, including the construction of a major epidemic treatment base and the relocation of the disease prevention and control center in Fangchenggang [1] - The collaboration between Guangxi People's Hospital and Fangchenggang First People's Hospital aims to establish the first regional medical center in the autonomous region, focusing on six key specialties, including cardiology [2] - The number of hospital beds per thousand people in Fangchenggang has increased from 4.23 in 2019 to 5.42 in 2024, indicating an expansion of quality medical resources [2] Group 3: Research and Innovation - A total of 2.3 billion RMB has been allocated to support the construction of a food safety and nutrition innovation platform and various research projects related to non-human primates, medical service models, drug treatment, and smart medicine [2] - The experimental zone has achieved breakthroughs in innovation and research, including the creation of the world's first non-alcoholic fatty liver disease model using non-human primates [2] - The Guangxi Luhang Biopharmaceutical Technology Co., Ltd. has received clinical approval for its targeted drugs AHT-101 and AHT-102 for gastric and pancreatic cancer [2]

证券代码：000516 证券简称：国际医学 公告编号：2025-023 西安国际医学投资股份有限公司 关于控股股东进行股票质押式回购交易的进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，世纪新元使用其持有的本公司部分股份与西部证券股份有限公司进 行的股票质押式回购交易已于近期办理了延期购回，具体事项如下： 二、控股股东股份累计质押的基本情况 截至公告披露日，控股股东及其一致行动人所持质押股份情况如下： | 股东 | 持股数量 | 持股比 | 本次质押延 | 本次质押延 | 占其所 | 占公 | 已质押股份 | 未质押股份 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | （股） | 例 | 期购回前累 | 期购回后累 | 持股份 | 司总 | 情况 | 情况 | 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次质押数 量（股） 占其 ...

Core Viewpoint - International Medicine (000516.SZ) is facing challenges in achieving profitability despite expanding its business directions and increasing service volumes in its hospitals [1][5][18] Financial Performance - In 2024, International Medicine reported revenue of 4.815 billion yuan, a year-on-year increase of 4.28%, but a net loss of 254 million yuan, although this represented a 31.01% reduction in losses compared to the previous year [2] - The first quarter of 2025 showed a slight increase in net loss to 106 million yuan, indicating a worsening trend in profitability [2] - The company has experienced continuous negative net profit for seven consecutive years, accumulating losses exceeding 3.8 billion yuan [9] Hospital Operations - The Xi'an Gaoxin Hospital and Xi'an International Medicine Center Hospital are key revenue contributors, with the latter being crucial for the company's overall profitability [6][7] - In 2024, the Xi'an Gaoxin Hospital achieved revenue of 1.525 billion yuan, a 2.68% increase, while the Xi'an International Medicine Center Hospital reported revenue of 3.274 billion yuan, a 7.60% increase, but still incurred a net loss of 165 million yuan [6] Service Volume Growth - The outpatient service volume at Xi'an Gaoxin Hospital reached 1.1545 million visits in 2024, a 0.30% increase, while inpatient services grew by 1.8% to 66,000 [3] - The Xi'an International Medicine Center Hospital (including the North Campus) saw outpatient service volume rise to 1.4182 million visits, an 18.88% increase [4] Strategic Initiatives - The company is exploring new business directions, including partnerships in gene testing and stem cell research, with a focus on clinical applications [8] - Collaborations with tech firms like Huawei and Mindray aim to integrate AI and big data into healthcare services, enhancing diagnostic accuracy and service quality [9] Competitive Landscape - The entry of new competitors in the market, such as Mingji Hospital, poses additional challenges for International Medicine, which must navigate a crowded field of healthcare providers [11][18] - The rapid expansion of new hospitals in Xi'an further intensifies competition, with six new tertiary hospitals established since 2023 [16][17]

Summary of Key Points Core Viewpoint The articles outline the revised articles of association for Xi'an International Medical Investment Co., Ltd., detailing the company's structure, governance, and operational guidelines in accordance with Chinese corporate laws. Group 1: Company Overview - Xi'an International Medical Investment Co., Ltd. was established as a joint-stock company in December 1986, originally as "Xi'an Liberation Department Store" [2][3] - The company underwent a restructuring in 1996 to comply with the Company Law and completed re-registration [3] - The registered capital of the company is RMB 2,258,201,153 [4] Group 2: Governance Structure - The company is governed by a board of directors, which includes independent directors, and a supervisory board [4][5] - The chairman of the board serves as the legal representative of the company [4] - The articles of association serve as a legally binding document for the company, shareholders, directors, supervisors, and senior management [4] Group 3: Share Structure - The company has a total of 2,258,201,153 shares, all of which are ordinary shares with equal rights [6][7] - Shares can be issued publicly or privately, and the company can also repurchase shares under specific conditions [7][8] - Shareholders are entitled to dividends and have voting rights proportional to their shareholdings [12][31] Group 4: Shareholder Rights and Responsibilities - Shareholders have the right to attend and vote at general meetings, receive dividends, and access company documents [12][31] - Shareholders must comply with laws and the articles of association, and they cannot withdraw their capital except in legally specified circumstances [36][37] - Major shareholders (holding over 5% of shares) must report any pledges of their shares to the company [38] Group 5: General Meeting Procedures - The company must hold an annual general meeting within six months after the end of the fiscal year [42] - Special meetings can be convened under certain conditions, such as significant losses or requests from major shareholders [43][48] - The notice for meetings must include details such as time, location, and agenda, and must be sent out in advance [55][56] Group 6: Voting and Resolutions - Resolutions can be classified as ordinary or special, with different voting thresholds required for approval [78][80] - Shareholders can vote in person or by proxy, and the company must provide facilities for remote voting [85][86] - Related party transactions require careful disclosure and must be approved by non-related shareholders [82][84]

西安国际医学投资股份有限公司 章 程 （2024 年度股东大会修订） 2025年5月15日 西安国际医学投资股份有限公司章程 （000516） 目 录 第四章 股东和股东大会 第七章 监事会 第九章 通知与公告 第 1 页 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第二节 解散和清算 第十一章 修改章程 第十二章 附则 西安国际医学投资股份有限公司章程 （000516） 第一章 总则 第一条 为维护公司、股东和债权人的合法权益,规范公司的组织 和行为,根据《中华人民共和国公司法》(以下简称《公司法》)、《中 华人民共和国证券法》(以下简称《证券法》)和其他有关规定,制订本 章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公 司。 西安国际医学投资股份有限公司（以下简称"公司"）的前身是"西 安市解放百货商场"。1986年12月4日，西安市第一商业局以"市一商 集字（86）398号"文件批准西安市解放百货商场改制为股份制试点企 业，1986年12月19日成立股份有限公司。1996年12月，公司按照《公司 法》进行了规范，并依法履行了重 ...

一、重要提示 证券代码：000516 证券简称：国际医学 公告编号：2025-022 西安国际医学投资股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本次股东大会会议召开期间没有增加、否决或变更提案。 二、会议召开和出席情况 1.现场会议召开时间：2025 年 5 月 15 日（星期四）下午 2:30 网络投票时间为：2025 年 5 月 15 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为： 2025 年 5 月 15 日的交易时间，即 09:15—09:25，09:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网系统投票的具体时间为：2025 年 5 月 15 日 09:15—15:00 期间任意时间。 2.现场会议召开地点：西安市高新区西太路 737 号西安国际医学中心 医院北院区保障楼 5 层会议室 3.召开方式：本次股东大会采取现场投票与网络投票相结合的方式 4.召集人：西安国际医学投资股份有限公司董事会 5.主持人：史今董事长 6.会议的召开符合《公司法》《上市公司股 ...

北 京 市 康 达 （ 西 安 ） 律 师 事 务 所 BEIJING KANGDA (XI'AN) LAW FIRM 陕西省西安市太白南路 139 号荣禾·云图中心 7 层、15 层 7&15F, Ronghe Cloud Centre, No.139, South Taibai Road, Xi'an, Shaanxi Province, P.R.C 邮编/Zip Code:710065 电话/Tel:029-88360128 传真/Fax:029-88360129 电话/Tel:（8629）88360127 / 88360128 / 88360726 传真/Fax：（8629） 北京市康达（西安）律师事务所 网址/Website：Http://www.kangdaxa.com 关于西安国际医学投资股份有限公司 2024 年年度股东大会的 法 律 意 见 书 致: 西安国际医学投资股份有限公司 北京市康达（西安）律师事务所接受西安国际医学投资股份有限公司（以下简 称"公司"）的委托，指派田慧律师、吕岩律师（以下简称"本所律师"）出席公 司 2024 年年度股东大会（以下简称"本次股东大会"），并出具法律意 ...

Core Insights - The 20th Meiwos International Medical Aesthetic Conference held in Hangzhou showcased the diverse charm and profound connotations of the medical aesthetics field, featuring over 200 experts and leaders discussing topics like technological innovation and market operations [1][6] - Milan Baiyu, as the organizer, emphasized its commitment to quality medical aesthetics and its leading position in the industry, supported by 21 years of academic accumulation and a focus on technical innovation [5][6] Group 1: Conference Highlights - The conference included 16 sub-forums focusing on various aspects of the medical aesthetics industry, providing a platform for in-depth discussions and sharing of clinical experiences [1] - The standardization forum highlighted the importance of compliance and operational standards in the medical aesthetics industry, with a focus on enhancing institutional competitiveness and customer trust [2] - The cosmetic surgery forum explored collaborative mechanisms and the latest surgical techniques, addressing consumer demands for natural and personalized aesthetic procedures [3] Group 2: Key Presentations - Yao Anyan, Director of Quality Management at Langzi Medical Aesthetics, presented on the value realization of a "compliant medical aesthetics" model, emphasizing the significance of compliance for long-term institutional development [2] - Xiao Minghui, Deputy Director of Marketing at Milan Baiyu, discussed the transition from VIP to VIC personalized services, highlighting the integration of AI in the medical aesthetics service chain [3] - Wang Peng, Deputy Director of the Minimally Invasive Center, shared insights on non-surgical double eyelid techniques, addressing the diverse aesthetic needs of modern consumers [4] Group 3: Company Positioning - Milan Baiyu has established itself as a core brand under Langzi Medical Aesthetics, continuously expanding its presence with 8 hospitals across 7 cities, driven by market trends and innovative aesthetic solutions [6] - The company aims to maintain its leadership in the medical aesthetics sector by focusing on innovation and exploration, looking forward to future collaborations with the Meiwos Conference [6]

5月15日，国际医学今日收盘5.2元，下跌1.33%，最新市净率3.29，总市值117.54亿元。 资金流向方面，5月15日，国际医学主力资金净流出609.47万元，近5日总体呈流入状态，5日共流入 936.34万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)7国际医学-45.99-46.253.29117.54亿行业平均 37.7943.763.40151.99亿行业中值38.8551.492.7248.17亿1润达医疗-303.46200.812.62111.01亿2何氏眼 科-136.34-118.641.7032.51亿3*ST生物-121.10-117.739.9523.37亿4普瑞眼科-68.82-61.822.9562.97亿5诚达 药业-68.70-117.701.5433.08亿6皓宸医疗-50.22-60.405.9622.76亿8创新医疗-42.40-47.342.5244.48亿9金域 医学-36.70-37.582.08143.29亿10百诚医药-29.24-71.391.4737.65亿11迪安诊断-23.32-26.201.4393.62亿 来源：金融界 西安国际医 ...

证券代码：000516 证券简称：国际医学 公告编号：2025-021 西安国际医学投资股份有限公司 活动时间：2025 年 5 月 20 日（星期二）15:00-17:00 活动地址："全景路演" 网址：https://rs.p5w.net。 为充分、高效与投资者进行沟通与交流，投资者可提前登录全景网 （https://ir.p5w.net/zj）进入"业绩说明会问题征集"向公司提问， 公司将在 2024 年度业绩说明会上对投资者普遍关注的问题进行交流。 特此公告。 关于参加"2025 年陕西辖区上市公司投资者集体 接待日暨 2024 年度业绩说明会"的公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度， 加强与广大投资者沟通交流，进一步提升投资者关系管理水平，陕西上 市公司协会在陕西证监局指导下，联合深圳市全景网络有限公司举办 "2025 年陕西辖区上市公司投资者集体接待日暨 2024 年度业绩说明 会"。 届时，公司总裁、副总裁兼董事会秘书、财务总监、独立董事及其 他相关工作人员将通过互动平台与投资 ...